

---

## Author Correction: Every step of the way: integrins in cancer progression and metastasis

*Hellyeh Hamidi and Johanna Ivaska*

*Nature Reviews Cancer* (2018) <https://doi.org/10.1038/s41568-018-0038-z>  
Published online 12 July 2018

In the originally published article, pertuzumab was incorrectly described as an anti-PI3K therapy in the section 'Integrins in anticancer therapy'. The sentence should read, "In mouse mammary tumour models, increased collagen levels and increased  $\beta$ 1 integrin and SRC activity have been demonstrated to accompany, and promote, combined resistance to anti-human epidermal growth factor receptor 2 (HER2; also known as ERBB2) (trastuzumab and pertuzumab) and anti-PI3K (buparlisib) therapies<sup>164</sup>." This has now been corrected in all versions of the original article.

<https://doi.org/10.1038/s41568-019-0112-1> | Published online 31 January 2019